NASDAQ:MTEM Molecular Templates (MTEM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Molecular Templates Stock (NASDAQ:MTEM) 30 days 90 days 365 days Advanced Chart Get Molecular Templates alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3,364 shsAverage Volume4.17 million shsMarket Capitalization$1,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMolecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.Read More… Receive MTEM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Templates and its competitors with MarketBeat's FREE daily newsletter. Email Address MTEM Stock News HeadlinesNasdaq to file Form 25-NSE with SEC to delist Molecular TemplatesDecember 20, 2024 | markets.businessinsider.comMolecular Templates, Inc. Faces Delisting from Nasdaq Due to Compliance IssuesDecember 19, 2024 | quiverquant.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 25, 2025 | Porter & Company (Ad)Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing RulesDecember 19, 2024 | globenewswire.comMolecular Templates Announces Key Leadership TransitionDecember 4, 2024 | markets.businessinsider.comMolecular Templates, Inc. Receives Nasdaq Deficiency Notification for Reporting and Bid Price ComplianceDecember 2, 2024 | quiverquant.comMolecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price RequirementsDecember 2, 2024 | globenewswire.comWhy Molecular Templates (MTEM) Stock Is Down 77% TodayOctober 14, 2024 | benzinga.comSee More Headlines MTEM Stock Analysis - Frequently Asked Questions How were Molecular Templates' earnings last quarter? Molecular Templates, Inc. (NASDAQ:MTEM) released its earnings results on Monday, November, 15th. The biotechnology company reported ($8.10) EPS for the quarter, missing analysts' consensus estimates of ($5.67) by $2.43. The biotechnology company earned $2.38 million during the quarter, compared to the consensus estimate of $15.69 million. Molecular Templates had a negative net margin of 61.35% and a negative trailing twelve-month return on equity of 260.50%. When did Molecular Templates' stock split? Molecular Templates shares reverse split before market open on Monday, August 14th 2023. The 1-15 reverse split was announced on Friday, August 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Molecular Templates? Shares of MTEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Molecular Templates own? Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Templates investors own include NVIDIA (NVDA), Meta Platforms (META), GE Aerospace (GE), Advanced Micro Devices (AMD), CymaBay Therapeutics (CBAY), Alibaba Group (BABA) and Catalyst Pharmaceuticals (CPRX). Company Calendar Last Earnings11/15/2021Today4/25/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:MTEM CIK1183765 Webwww.mtem.com Phone(512) 869-1555Fax650-474-2529Employees260Year Founded2009Profitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,120,000.00 Net Margins-61.35% Pretax Margin-61.39% Return on Equity-260.50% Return on Assets-46.90% Debt Debt-to-Equity RatioN/A Current Ratio1.56 Quick Ratio1.56 Sales & Book Value Annual Sales$23.48 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / BookN/AMiscellaneous Outstanding Shares6,584,000Free Float5,669,000Market Cap$1,000.00 OptionableNo Data Beta1.53 Social Links Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:MTEM) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Templates, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Templates With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.